Reuters logo
BRIEF-Alembic Pharmaceuticals gets U.S. FDA tentative approval for Dabigatran Etexilate Capsules
July 10, 2017 / 5:21 AM / in 3 months

BRIEF-Alembic Pharmaceuticals gets U.S. FDA tentative approval for Dabigatran Etexilate Capsules

July 10 (Reuters) - Alembic Pharmaceuticals Ltd

* Says alembic pharmaceuticals receives USFDA tentative approval for Dabigatran Etexilate Capsules, 150 mg.

* Dabigatran etexilate capsules are indicated to reduce risk of stroke and systemic embolism

Source text for Eikon:

Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below